RecruitingNCT06382519
Thalidomide Therapy for VEOIBD
Thalidomide Therapy for Very Early Onset Inflammatory Bowel Disease
Sponsor
Children's Hospital of Fudan University
Enrollment
40 participants
Start Date
May 15, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease
Eligibility
Min Age: 28 DaysMax Age: 6 Years
Inclusion Criteria4
- diagnosed with inflammatory bowel disease
- disease onset less than 6 years old
- Pediatric Crohn's disease Activity Index (PCDAI)>30 or Pediatric Ulcerative Colitis Activity Index (PUCAI)>35
- patients and their legal guardians were willing to receive thalidomide treatment and participate in this study.
Exclusion Criteria7
- liver dysfunction
- allergy to thalidomide
- with Neuropathy
- with thrombosis
- thalidomide treatment in the previous 30 days
- biologics treatment in the previous 8 weeks
- not suitable participated in this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGThalidomide
thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06382519
Related Trials
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
NCT062867095 locations
Predictors of Prognosis in IBD Patients
NCT056530111 location
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395175 locations
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
NCT060946081 location
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
NCT063151791 location